Superworth

Arbutus Biopharma price to sales ratio ABUS

Market value divided by revenue over the last twelve months, since 2014.

Today, Oct 23, 2026
4.6×
10-year median
33.7×
Against its 10-year history
1st
percentile: 0 is its lowest day, 100 its highest
10-year range
4.4× to 195×
Peer median
1.5×

Arbutus Biopharma's price to sales ratio is 4.6× as of Oct 23, 2026.

That is below its ten-year median of 33.7×, lower than on 99% of days in the last ten years.

Over that time it ranged from 4.4× in May 2026 to 195× in Sep 2017.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far4.6×4.4×65.5×
202562.9×41.9×111×
202490.2×17.4×105×
202318.8×10.5×18.8×
202210.1×8.6×46.6×
202151.8×33.5×60.6×
202049.0×10.4×60.1×
201923.3×10.9×41.5×
201831.6×19.7×54.1×
201734.9×9.7×195×
20169.3×8.5×13.3×
201514.7×14.7×60.7×
201417.4×15.6×20.4×

Against its peers

Companies in Drug Manufacturers - General nearest Arbutus Biopharma's size, closest first, today.

CompanyPrice to sales ratio
ABUSArbutus Biopharma4.6×
COLLCollegium Pharmaceutical0.9×
AMPHAmphastar Pharmaceuticals1.5×
CRMDCorMedix1.3×
ZVRAZevra Therapeutics4.3×
OMEROmerosn/m
IRWDIronwood Pharmaceuticals1.5×
PBYIPuma Biotechnology2.5×
ARVNArvinas1.5×
PCRXPacira BioSciences1.9×
ANABAnaptysbion/m
Peer median1.5×

Where Arbutus Biopharma ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Arbutus Biopharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.